Eyenovia Inc (EYEN)
0.6282
-0.08
(-11.68%)
USD |
NASDAQ |
Apr 26, 16:00
0.6332
0.00 (0.00%)
After-Hours: 20:00
Eyenovia SG&A Expense (Quarterly): 3.402M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 3.402M |
September 30, 2023 | 2.942M |
June 30, 2023 | 3.150M |
March 31, 2023 | 2.937M |
December 31, 2022 | 3.170M |
September 30, 2022 | 3.353M |
June 30, 2022 | 3.535M |
March 31, 2022 | 3.475M |
December 31, 2021 | 3.655M |
September 30, 2021 | 2.373M |
June 30, 2021 | 2.298M |
March 31, 2021 | 2.244M |
December 31, 2020 | 1.957M |
September 30, 2020 | 1.728M |
June 30, 2020 | 2.104M |
Date | Value |
---|---|
March 31, 2020 | 1.837M |
December 31, 2019 | 1.964M |
September 30, 2019 | 1.490M |
June 30, 2019 | 1.809M |
March 31, 2019 | 1.943M |
December 31, 2018 | 2.058M |
September 30, 2018 | 1.833M |
June 30, 2018 | 0.9088M |
March 31, 2018 | 1.338M |
December 31, 2017 | 0.5799M |
September 30, 2017 | 0.3149M |
June 30, 2017 | 0.2249M |
March 31, 2017 | 0.196M |
December 31, 2016 | 0.1768M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.490M
Minimum
Sep 2019
3.655M
Maximum
Dec 2021
2.601M
Average
2.373M
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
NovaBay Pharmaceuticals Inc | 2.609M |
Alpine Immune Sciences Inc | 6.374M |
Lantern Pharma Inc | 1.304M |
Oragenics Inc | 1.754M |
MAIA Biotechnology Inc | 2.660M |